OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Skarbnik on Future Combination Therapies With Tazemetostat in Follicular Lymphoma

September 29th 2020

Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.

Dr. Petrylak on Pivotal PARP Inhibitor Trials in mCRPC With DNA Repair Mutations

September 28th 2020

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Dr. Skarbnik on the Approval of Tazemetostat in Relapsed/Refractory Follicular Lymphoma

September 28th 2020

Alan P. Z. Skarbnik, MD, highlights the approval of tazemetostat in relapsed/refractory follicular lymphoma.

Dr. Rampal on Challenges With Targeting High-Risk Mutations in Myelofibrosis

September 28th 2020

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL

September 28th 2020

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

Dr. Burke on Risk Stratification Strategies in Follicular Lymphoma

September 28th 2020

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma.

Dr. Azad on the Post-Hoc Analysis of the ARCHES Study in mHSPC

September 28th 2020

Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.

Dr. Petrylak on the Role of PSA Screening in Prostate Cancer

September 28th 2020

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

Dr. Batlevi on Emerging Therapies in Follicular Lymphoma

September 25th 2020

Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.

Dr. Skarbnik on the Utility of PI3K Inhibitors in Follicular Lymphoma

September 25th 2020

Alan P. Z. Skarbnik, discusses ongoing research with PI3K inhibitors in follicular lymphoma.

Dr. Burke on Treatment Options in Relapsed/Refractory Follicular Lymphoma

September 25th 2020

John M. Burke, MD, discusses treatment options in relapsed/refractory follicular lymphoma.

Dr. Hussain on the Importance of Genomic Profiling in mCRPC

September 25th 2020

Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.

Dr. Nguyen on Standard and Investigational Treatment Options in High-Risk Prostate Cancer

September 25th 2020

Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.

Dr. Levy on the DFS Benefit Achieved With Adjuvant Osimertinib in EGFR+ NSCLC

September 25th 2020

Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.

Dr. Vokes on Investigative Biomarkers of Response to Checkpoint Inhibitors in Cancer

September 25th 2020

Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.

Dr. Azad on Unmet Needs in Metastatic Hormone-Sensitive Prostate Cancer

September 25th 2020

Arun Azad, PhD, discusses unmet needs for men with metastatic hormone-sensitive prostate cancer.

Dr. Nixon on the Role of MSI in Cancer

September 24th 2020

Andrew B. Nixon, PhD, MBA, discusses the role of microsatellite instability in cancer.

Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

September 24th 2020

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBC

September 24th 2020

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

Dr. Ma on the Utility of BTK Inhibitors in Relapsed/Refractory CLL

September 24th 2020

Shuo Ma, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory chronic lymphocytic leukemia.